drugset / Trial / NCT01053910

Ramipril 10 mg/Day Prevention

NCT01053910

Phase 4 Completed 1012 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective is to investigate the safety of ramipril 10 mg/day used in prevention of cardiovascular events in high-risk patients, including the criteria of the HOPE study.

Timeline

Start
2003-10
Primary completion
2005-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramipril Small molecule 10 mg

Indications